^
Association details:
Biomarker:EML4-ALK + ALK-PEX13
Cancer:Sarcoma
Drug:Xalkori (crizotinib) (ALK inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C4 – Case Studies
Source:
Title:

Loss of 5'ALK leads to better response to crizotinib in sarcomas with ALK rearrangement

Published date:
05/19/2021
Excerpt:
Case #4 is an undifferentiated sarcoma with EML4-ALK fusion...All cases received and responded to Crizotinib therapy, with the Karnofsky Performance Status (KPS) improved from 30-60 score pre-therapy to 90-100 score after 3 months of Crizotinib.…Case#3 and #4, both retained the 5'ALK, relapsed at 9.4 m and 6.1 m…
DOI:
10.1200/JCO.2021.39.15_suppl.e23554